Press Releases

February 14, 2012 - OptiNose Announces First Patient Enrolled in Phase III Study of Sumatriptan Powder Delivered Intranasally with Innovative Bi-directional Device

February 2, 2012 - OptiNose Files Investigational New Drug Application to use Sumatriptan Delivered with its Novel Drug Delivery Technology

August 1, 2011 - OptiNose Announces Additional Leadership Team Members

May 23, 2011 - OptiNose Bi-Directional Drug Delivery Technology Wins Innovation Award for Potential Benefits of Nose to Brain Application

November 3, 2010 - OptiNose Receives Nearly $489,000 Grant Award under U.S. Government Qualifying Therapeutic Discovery Project Program

October 28, 2010 - Rapid Absorption Rate Alone May Not Explain Efficacy in Migraines of Sumatriptan Delivered with OptiNose's Novel Drug Delivery Technology

October 20, 2010 - New Data Shows Therapeutic Benefits in Chronic Rhinosinusitis Patients Using Fluticasone Delivered by OptiNose's Novel Delivery Technology

August 10, 2010 - Subgroup Analysis Evaluating Efficacy of Fluticasone Delivered with Novel Drug Delivery Technology

June 7, 2010 - Avista Capital Partners Invests in OptiNose

December 1, 2009 - New Data on Highly Effective Treatment for Chronic Rhinosinusitis with Nasal Polyps

April 17, 2009 - OptiNose presents new data on highly effective treatment for chronic rhinosinusitis

April 17, 2009 - Upcoming Event - April 17, 2009 - Rhinology World 2009 Presentation

April 1, 2009 - Upcoming Event - April 1, 2009 - Nasal Drug Delivery Conference Presentation

September 20, 2008 - Upcoming Event - September 20, 2008 - American Rhinology Society Presentation

September 19, 2008 - OptiNose Presents Data On Highly Effective Nasal Polyp Treatment

June 29, 2008 - American Headache Society - Phase II Migraine (Poster PDF, 652KB)

June 28, 2008 - OptiNose Presents Data on Highly Effective Migraine Treatment

April 18, 2008 - American Academy of Neurology - Phase I Migraine (Poster PDF, 1.1MB)

April 17, 2008 - OptiNose Nasal Delivery of Sumatriptan Proves as Effective as Subcutaneous Injection

March 23, 2008 - Phase I Human Insulin Data

December 5, 2007 - New Phase II Data for Nasal Polyposis

November 5, 2007 - OptiNose Completes Phase II Study in Migraine

October 5, 2007 - OptiNose Initiates Phase II Study in Chronic Rhinosinusitis

December 20, 2006 - OptiNose Completes Phase I Study with Triptan

October 23, 2006 - OptiNose Completes Phase I Study with Topical Steroid

Breath-Powered Nasal Delivery

A Message from Peter Miller

Partnership Opportunities

The OptiNose technology has unique capabilities that may be ideally suited to solving your specific delivery challenges.